Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Sezzle Inc (SEZL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Sezzle Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287.53 (market cap $39.89B), while Sezzle Inc trades at $170.2 (market cap $6.03B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 6.6× Sezzle Inc's market cap, and Sezzle Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | SEZL | |
|---|---|---|
Market Cap | $39.89B | $6.03B |
Sector | Health | Technology |
52-Week High | $491.22 | $183.24 |
52-Week Low | $278.09 | $50.97 |
Enterprise Value | $38.15B | $6.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
SEZL trades at $179.38, up 1.3% today, with a bullish technical signal and strong earnings momentum after beating EPS estimates for three consecutive quarters. The stock exhibits high profitability with a 30.83% net income margin and 91.95% ROE, though valuation multiples like a P/E of 42.78 suggest premium pricing. Recent news highlights product expansion and raised guidance, supporting positive sentiment.
Outlook remains favorable given robust growth and operational leverage, but risks include high valuation sensitivity and regulatory scrutiny. Analyst consensus is bullish with a $149.50 price target, though current price exceeds this, indicating potential near-term consolidation. Investment appeal hinges on sustained execution amid competitive fintech dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
